Advertisement
Advertisement

BBIO

BBIO logo

BridgeBio Pharma, Inc. Common Stock

76.60
USD
Sponsored
-2.08
-2.64%
Aug 28, 16:00 UTC -4
Closed
exchange

After-Market

76.86

+0.27
+0.35%

BBIO Earnings Reports

Positive Surprise Ratio

BBIO beat 8 of 29 last estimates.

28%

Next Report

Date of Next Report
Oct 27, 2026
Estimate for Q3 26 (Revenue/ EPS)
$271.51M
/
-$0.59
Implied change from Q2 26 (Revenue/ EPS)
+11.42%
/
-24.36%
Implied change from Q3 25 (Revenue/ EPS)
+124.95%
/
-37.89%

BridgeBio Pharma, Inc. Common Stock earnings per share and revenue

On Aug 10, 2026, BBIO reported earnings of -0.78 USD per share (EPS) for Q2 26, missing the estimate of -0.59 USD, resulting in a -31.07% surprise. Revenue reached 243.68 million, compared to an expected 223.12 million, with a 9.21% difference. The market reacted with a -1.15% price change (close before vs. close after earnings).
Looking ahead to Q3 26, 13 analysts forecast an EPS of -0.59 USD, with revenue projected to reach 271.51 million USD, implying an decrease of -24.36% EPS, and increase of 11.42% in Revenue from the last quarter.

Industry Peers’ Earnings

Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.

logo
Sol-Gel Technologies Ltd. Ordinary Shares
Report Date
Aug 20, 2026 For Q2 26
Estimate
-$2.35
Actual
-$1.12
Surprise
+52.04%
FAQ
For Q2 2026, BridgeBio Pharma, Inc. Common Stock reported EPS of -$0.78, missing estimates by -31.07%, and revenue of $243.68M, 9.21% above expectations.
The stock price moved down -1.15%, changed from $84.67 before the earnings release to $83.70 the day after.
The next earning report is scheduled for Oct 27, 2026.
Based on 13 analysts, BridgeBio Pharma, Inc. Common Stock is expected to report EPS of -$0.59 and revenue of $271.51M for Q3 2026.
Check FXEmpire's Earnings Calendar for today's list of reporting companies.
Advertisement